A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects
Completed · Phase 2 · Has a placebo group
Conditions studied: NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, NAFLD - Nonalcoholic Fatty Liver Disease
In brief
This is a randomized, single-blind, placebo-controlled, once daily (QD) dose study of CRV431 in presumed NASH F2/F3 subjects.
Key facts
- Study ID
- NCT04480710
- Run by
- Hepion Pharmaceuticals, Inc.
- People needed
- 47
- Starts
- 2020-06-23
- Expected to finish
- 2021-10-30
- Last updated by the study team
- 2022-07-15
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Conquest Clinical Research — Orange, California, United States
- Alliance Clinical Research — Poway, California, United States
- La Salud Research, Inc. — Miami, Florida, United States
- Progressive Medical Research — Port Orange, Florida, United States
- Covenant Research, LLC. — Sarasota, Florida, United States
- Gastrointestinal Specialists of Georgia — Marietta, Georgia, United States
- Aventiv Research Inc. — Columbus, Ohio, United States
- Quality Research Inc. — San Antonio, Texas, United States
- Pinnacle Research Group — San Antonio, Texas, United States
- FDI Clinical Research — San Juan, Puerto Rico
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.